1. Home
  2. SBGI vs MNKD Comparison

SBGI vs MNKD Comparison

Compare SBGI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$13.66

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.79

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
MNKD
Founded
1986
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
SBGI
MNKD
Price
$13.66
$3.79
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$22.00
$8.69
AVG Volume (30 Days)
357.1K
3.1M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
6.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,169,000,000.00
$348,966,000.00
Revenue This Year
$12.37
$35.81
Revenue Next Year
N/A
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$12.46
$2.23
52 Week High
$17.88
$6.51

Technical Indicators

Market Signals
Indicator
SBGI
MNKD
Relative Strength Index (RSI) 43.61 42.08
Support Level $13.13 $3.77
Resistance Level $14.48 $4.23
Average True Range (ATR) 0.41 0.16
MACD -0.08 -0.03
Stochastic Oscillator 21.01 0.85

Price Performance

Historical Comparison
SBGI
MNKD

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: